Ascelia Pharma (Q1 review): PDUFA-date closing in - Redeye
Redeye comments on Ascelia's Q1 report and recent development in the company. We see two clear triggers ahead: The PDUFA-date on the 3rd of July and a potential licensing agreement.
ANNONS
Redeye comments on Ascelia's Q1 report and recent development in the company. We see two clear triggers ahead: The PDUFA-date on the 3rd of July and a potential licensing agreement.
